tiprankstipranks
Trending News
More News >
BioNTech SE (BNTX)
NASDAQ:BNTX
US Market
Advertisement

BioNTech SE (BNTX) Stock Forecast & Price Target

Compare
4,630 Followers
See the Price Targets and Ratings of:

BNTX Analyst Ratings

Moderate Buy
19Ratings
Moderate Buy
14 Buy
5 Hold
0 Sell
Based on 19 analysts giving stock ratings to
BioNTech
SE
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BNTX Stock 12 Month Forecast

Average Price Target

$138.59
▲(29.11%Upside)
Based on 19 Wall Street analysts offering 12 month price targets for BioNTech SE in the last 3 months. The average price target is $138.59 with a high forecast of $181.00 and a low forecast of $108.49. The average price target represents a 29.11% change from the last price of $107.34.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"79":"$79","182":"$182","104.75":"$104.8","130.5":"$130.5","156.25":"$156.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":181,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$181.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":138.59,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$138.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":108.49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$108.49</span>\n  </div></div>","useHTML":true}}],"tickPositions":[79,104.75,130.5,156.25,182],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.34,113.00615384615385,118.6723076923077,124.33846153846154,130.0046153846154,135.67076923076922,141.33692307692309,147.00307692307692,152.66923076923078,158.3353846153846,164.00153846153847,169.6676923076923,175.33384615384614,{"y":181,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.34,109.74384615384616,112.14769230769231,114.55153846153847,116.95538461538462,119.35923076923078,121.76307692307692,124.16692307692308,126.57076923076923,128.9746153846154,131.37846153846155,133.78230769230768,136.18615384615384,{"y":138.59,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,107.34,107.42846153846155,107.51692307692308,107.60538461538462,107.69384615384615,107.7823076923077,107.87076923076923,107.95923076923077,108.0476923076923,108.13615384615385,108.22461538461538,108.31307692307692,108.40153846153845,{"y":108.49,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":80.68,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.22,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.93,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.77,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.43,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$181.00Average Price Target$138.59Lowest Price Target$108.49
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on BNTX
TipRanks AITipRanks
Not Ranked
TipRanks
$110
Hold
2.48%
Upside
Reiterated
08/01/25
BioNTech's overall score is primarily impacted by mixed financial performance and a challenging valuation due to unprofitability. Technical analysis and earnings call sentiment provide some positive notes, but are overshadowed by financial and operational challenges. The company's strong cash position and advancements in oncology programs are promising but need to translate into improved financial outcomes.
Clear Street Analyst forecast on BNTX
William MaughanClear Street
Clear Street
$181$185
Buy
72.35%
Upside
Reiterated
08/04/25
BioNTech price target raised to $185 from $181 at Clear StreetBioNTech price target raised to $185 from $181 at Clear Street
Morgan Stanley Analyst forecast on BNTX
Terence FlynnMorgan Stanley
Morgan Stanley
$133
Buy
23.91%
Upside
Reiterated
08/04/25
Morgan Stanley Reaffirms Their Buy Rating on BioNTech SE (BNTX)Overweight rating with EPS revisions (F25: -5.61 to -5.54; F26: -2.19 to -2.16) while Price Target remains unchanged.
J.P. Morgan Analyst forecast on BNTX
Jessica FyeJ.P. Morgan
J.P. Morgan
$116
Hold
8.07%
Upside
Reiterated
07/17/25
J.P. Morgan Sticks to Its Hold Rating for BioNTech SE (BNTX)
Bank of America Securities Analyst forecast on BNTX
Tazeen AhmadBank of America Securities
Bank of America Securities
$127$126
Buy
17.38%
Upside
Reiterated
07/15/25
BioNTech SE (BNTX) Gets a Buy from Bank of America Securities
BMO Capital Analyst forecast on BNTX
Evan SeigermanBMO Capital
BMO Capital
$143
Buy
33.22%
Upside
Reiterated
07/09/25
BioNTech SE (BNTX) Receives a Buy from BMO Capital
Truist Financial Analyst forecast on BNTX
Asthika GoonewardeneTruist Financial
Truist Financial
Buy
Reiterated
06/27/25
Truist Financial Remains a Buy on BioNTech SE (BNTX)
Citi
$140
Buy
30.43%
Upside
Reiterated
06/25/25
Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Thermo Fisher (TMO)
H.C. Wainwright Analyst forecast on BNTX
Robert BurnsH.C. Wainwright
H.C. Wainwright
$138
Buy
28.56%
Upside
Reiterated
06/25/25
BioNTech SE: Orphan Drug Designation and Valuation Support Buy Rating
Deutsche Bank  Analyst forecast on BNTX
Emmanuel PapadakisDeutsche Bank
Deutsche Bank
$140
Buy
30.43%
Upside
Reiterated
06/13/25
Deutsche Bank Remains a Buy on BioNTech SE (BNTX)
Canaccord Genuity Analyst forecast on BNTX
John NewmanCanaccord Genuity
Canaccord Genuity
$171
Buy
59.31%
Upside
Reiterated
06/12/25
BioNTech's Strategic Acquisition of CureVac: Enhancing mRNA Platform and Market Position
Leerink Partners Analyst forecast on BNTX
Daina GrayboschLeerink Partners
Leerink Partners
Buy
Reiterated
06/12/25
Analysts Are Bullish on Top Healthcare Stocks: Schrodinger (SDGR), Celldex (CLDX)
Berenberg Bank Analyst forecast on BNTX
Harry GillisBerenberg Bank
Berenberg Bank
$130$150
Buy
39.74%
Upside
Reiterated
06/03/25
Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Sanofi (SNYNF)
Jefferies Analyst forecast on BNTX
Akash TewariJefferies
Jefferies
$149$151
Buy
40.67%
Upside
Reiterated
06/02/25
Jefferies Keeps Their Buy Rating on BioNTech SE (BNTX)
Oppenheimer Analyst forecast on BNTX
Hartaj SinghOppenheimer
Oppenheimer
Hold
Reiterated
06/02/25
Oppenheimer Sticks to Their Hold Rating for BioNTech SE (BNTX)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on BNTX
TipRanks AITipRanks
Not Ranked
TipRanks
$110
Hold
2.48%
Upside
Reiterated
08/01/25
BioNTech's overall score is primarily impacted by mixed financial performance and a challenging valuation due to unprofitability. Technical analysis and earnings call sentiment provide some positive notes, but are overshadowed by financial and operational challenges. The company's strong cash position and advancements in oncology programs are promising but need to translate into improved financial outcomes.
Clear Street Analyst forecast on BNTX
William MaughanClear Street
Clear Street
$181$185
Buy
72.35%
Upside
Reiterated
08/04/25
BioNTech price target raised to $185 from $181 at Clear StreetBioNTech price target raised to $185 from $181 at Clear Street
Morgan Stanley Analyst forecast on BNTX
Terence FlynnMorgan Stanley
Morgan Stanley
$133
Buy
23.91%
Upside
Reiterated
08/04/25
Morgan Stanley Reaffirms Their Buy Rating on BioNTech SE (BNTX)Overweight rating with EPS revisions (F25: -5.61 to -5.54; F26: -2.19 to -2.16) while Price Target remains unchanged.
J.P. Morgan Analyst forecast on BNTX
Jessica FyeJ.P. Morgan
J.P. Morgan
$116
Hold
8.07%
Upside
Reiterated
07/17/25
J.P. Morgan Sticks to Its Hold Rating for BioNTech SE (BNTX)
Bank of America Securities Analyst forecast on BNTX
Tazeen AhmadBank of America Securities
Bank of America Securities
$127$126
Buy
17.38%
Upside
Reiterated
07/15/25
BioNTech SE (BNTX) Gets a Buy from Bank of America Securities
BMO Capital Analyst forecast on BNTX
Evan SeigermanBMO Capital
BMO Capital
$143
Buy
33.22%
Upside
Reiterated
07/09/25
BioNTech SE (BNTX) Receives a Buy from BMO Capital
Truist Financial Analyst forecast on BNTX
Asthika GoonewardeneTruist Financial
Truist Financial
Buy
Reiterated
06/27/25
Truist Financial Remains a Buy on BioNTech SE (BNTX)
Citi
$140
Buy
30.43%
Upside
Reiterated
06/25/25
Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Thermo Fisher (TMO)
H.C. Wainwright Analyst forecast on BNTX
Robert BurnsH.C. Wainwright
H.C. Wainwright
$138
Buy
28.56%
Upside
Reiterated
06/25/25
BioNTech SE: Orphan Drug Designation and Valuation Support Buy Rating
Deutsche Bank  Analyst forecast on BNTX
Emmanuel PapadakisDeutsche Bank
Deutsche Bank
$140
Buy
30.43%
Upside
Reiterated
06/13/25
Deutsche Bank Remains a Buy on BioNTech SE (BNTX)
Canaccord Genuity Analyst forecast on BNTX
John NewmanCanaccord Genuity
Canaccord Genuity
$171
Buy
59.31%
Upside
Reiterated
06/12/25
BioNTech's Strategic Acquisition of CureVac: Enhancing mRNA Platform and Market Position
Leerink Partners Analyst forecast on BNTX
Daina GrayboschLeerink Partners
Leerink Partners
Buy
Reiterated
06/12/25
Analysts Are Bullish on Top Healthcare Stocks: Schrodinger (SDGR), Celldex (CLDX)
Berenberg Bank Analyst forecast on BNTX
Harry GillisBerenberg Bank
Berenberg Bank
$130$150
Buy
39.74%
Upside
Reiterated
06/03/25
Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Sanofi (SNYNF)
Jefferies Analyst forecast on BNTX
Akash TewariJefferies
Jefferies
$149$151
Buy
40.67%
Upside
Reiterated
06/02/25
Jefferies Keeps Their Buy Rating on BioNTech SE (BNTX)
Oppenheimer Analyst forecast on BNTX
Hartaj SinghOppenheimer
Oppenheimer
Hold
Reiterated
06/02/25
Oppenheimer Sticks to Their Hold Rating for BioNTech SE (BNTX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioNTech SE

1 Month
xxx
Success Rate
15/27 ratings generated profit
56%
Average Return
+2.03%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +2.03% per trade.
3 Months
xxx
Success Rate
7/11 ratings generated profit
64%
Average Return
+0.28%
reiterated a xxx
rating 23 hours ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +0.28% per trade.
1 Year
Tazeen AhmadBank of America Securities
Success Rate
14/24 ratings generated profit
58%
Average Return
+0.72%
reiterated a buy rating 21 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +0.72% per trade.
2 Years
xxx
Success Rate
16/24 ratings generated profit
67%
Average Return
+4.20%
reiterated a xxx
rating 21 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +4.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BNTX Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
8
11
8
6
3
Buy
35
46
50
42
25
Hold
4
12
15
15
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
47
69
73
63
36
In the current month, BNTX has received 28 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. BNTX average Analyst price target in the past 3 months is 138.59.
Each month's total comprises the sum of three months' worth of ratings.

BNTX Financial Forecast

BNTX Earnings Forecast

Next quarter’s earnings estimate for BNTX is -$0.85 with a range of -$3.89 to $1.22. The previous quarter’s EPS was -$1.85. BNTX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.15% of the time in the same period. In the last calendar year BNTX has Preformed in-line its overall industry.
Next quarter’s earnings estimate for BNTX is -$0.85 with a range of -$3.89 to $1.22. The previous quarter’s EPS was -$1.85. BNTX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.15% of the time in the same period. In the last calendar year BNTX has Preformed in-line its overall industry.

BNTX Sales Forecast

Next quarter’s sales forecast for BNTX is $765.71M with a range of $193.81M to $1.17B. The previous quarter’s sales results were $260.80M. BNTX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.21% of the time in the same period. In the last calendar year BNTX has Preformed in-line its overall industry.
Next quarter’s sales forecast for BNTX is $765.71M with a range of $193.81M to $1.17B. The previous quarter’s sales results were $260.80M. BNTX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.21% of the time in the same period. In the last calendar year BNTX has Preformed in-line its overall industry.

BNTX Stock Forecast FAQ

What is BNTX’s average 12-month price target, according to analysts?
Based on analyst ratings, BioNTech SE’s 12-month average price target is 138.59.
    What is BNTX’s upside potential, based on the analysts’ average price target?
    BioNTech SE has 29.11% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BNTX a Buy, Sell or Hold?
          BioNTech SE has a consensus rating of Moderate Buy which is based on 14 buy ratings, 5 hold ratings and 0 sell ratings.
            What is BioNTech SE’s price target?
            The average price target for BioNTech SE is 138.59. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $181.00 ,the lowest forecast is $108.49. The average price target represents 29.11% Increase from the current price of $107.34.
              What do analysts say about BioNTech SE?
              BioNTech SE’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of BNTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis